We support people with disabilities. More than 2,800 clients of all ages count on us for living and working, day care and leisure, for 24/7 intensive care or limited, occasional support. Every day, 2,500 professionals and 1,000 volunteers are ready for them, in almost 100 locations or in their own or parental home in the Southeast Brabant region.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

news image

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More

MedTech, Industrial Impact

CONCERTAI RELEASES CTO 2.0, A NEXT GENERATION AI SAAS SOLUTION FOR ONCOLOGY CLINICAL TRIAL DESIGN AND OPTIMIZATION

Prnewswire | April 06, 2023

news image

ConcertAI, LLC a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence solutions for life sciences and healthcare, announced the release of its next generation of Clinical Trial Optimization (CTO 2.0). "Trial sponsors have a range of new imperatives they're trying to meet: assuring that the trial population is reflective of the ultimate population that would have access to the drug; to set and meet diversity goals for those ethnic, racial and econ...

Read More

Cell and Gene Therapy

VADERIS THERAPEUTICS AG EMERGES FROM STEALTH AND ANNOUNCES INITIATION OF CLINICAL PROOF-OF-CONCEPT TRIAL IN HHT

Vaderis Therapeutics AG | August 22, 2022

news image

Vaderis Therapeutics AG a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announced its emergence from stealth and initiation of its INSIGHT proof-of-concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia also known as Osler-Weber-Rendu Syndrome. Vaderis was established in 2019 and in 2020 raised over CHF18 million from Medicxi, enabling progression of its lead asset into the c...

Read More

Cell and Gene Therapy

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

news image

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More
news image

Medical, Industry Outlook

QURALIS AND UNLEARN ANNOUNCE COLLABORATION TO ACCELERATE AND OPTIMIZE ALS CLINICAL TRIALS WITH GENERATIVE ARTIFICIAL INTELLIGENCE TECHNOLOGIES

PRNewswire | June 28, 2023

QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, and Unlearn, a pioneering technology company innovating machine learning to revolutionize medical research, today announced they have entered into a collaboration to accelerate and optimize QurAlis' clinical program in ALS with Unlearn's advanced generative artificial ...

Read More
news image

MedTech, Industrial Impact

CONCERTAI RELEASES CTO 2.0, A NEXT GENERATION AI SAAS SOLUTION FOR ONCOLOGY CLINICAL TRIAL DESIGN AND OPTIMIZATION

Prnewswire | April 06, 2023

ConcertAI, LLC a leader in AI Software-as-a-Service (SaaS) technology and Real-world Evidence solutions for life sciences and healthcare, announced the release of its next generation of Clinical Trial Optimization (CTO 2.0). "Trial sponsors have a range of new imperatives they're trying to meet: assuring that the trial population is reflective of the ultimate population that would have access to the drug; to set and meet diversity goals for those ethnic, racial and econ...

Read More
news image

Cell and Gene Therapy

VADERIS THERAPEUTICS AG EMERGES FROM STEALTH AND ANNOUNCES INITIATION OF CLINICAL PROOF-OF-CONCEPT TRIAL IN HHT

Vaderis Therapeutics AG | August 22, 2022

Vaderis Therapeutics AG a clinical stage biotechnology company focused on developing treatments for rare diseases associated with vascular malformations, today announced its emergence from stealth and initiation of its INSIGHT proof-of-concept clinical trial in patients suffering from Hereditary Haemorrhagic Telangiectasia also known as Osler-Weber-Rendu Syndrome. Vaderis was established in 2019 and in 2020 raised over CHF18 million from Medicxi, enabling progression of its lead asset into the c...

Read More
news image

Cell and Gene Therapy

PULMATRIX ANNOUNCES PATIENT DOSING COMPLETED FOR ITS NOVEL INHALED THERAPY PUR3100 FOR ACUTE MIGRAINE

Pulmatrix, Inc. | September 27, 2022

Pulmatrix, Inc. a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious disease using its patented iSPERSE™ technology, today announced that all subjects have completed dosing in a Phase 1 trial evaluating PUR3100, a novel orally inhaled formulation of dihydroergotamine in healthy volunteers. Phase 1 data from this study is expected in Q4 2022. The Phase 1 trial has a double-dummy, double-blinded design to assesses the safety, to...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us